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Abstract
Murine embryonic limb cultures have invaluable roles in studying skeletogenesis. Substance
delivery is an underdeveloped area in developmental biology that has primarily relied on Affi-Gel-
Blue-Agarose-beads. However, the lack of information about the efficiency of agarose-bead
loading and release and difficulties for a single-bead implantation represent significant limitations.
We optimized the use of glycol-chitosan–5β-cholanic-acid-conjugates (HGC) as a novel protein
delivery system in mouse embryonic limbs. To this purpose, we loaded HGC either with
recombinant Noggin, or bovine serum albumin (BSA). The size, morphology and stability of the
protein-loaded-HGC were determined by transmission-electron-microscopy and dynamic-light-
scattering. HGC-BSA and HGC-Noggin loading efficiencies were 80-90%. Time-course study
revealed that Noggin and BSA were 80-90% of released after 48-hours. We developed several
techniques to implant protein-loaded-HGC into murine embryonic joints from embryonic age
(E)13.5 to E15.5, including a micro-injection system dispensing nanoliters. HGC did not interfere
with skeletogenesis. Using CBR-3BA staining, we detected HGC-nanoparticles within implanted
tissues. Furthermore, a sustained release of BSA and Noggin was demonstrated in HGC-BSA and
HGC-Noggin injected regions. HGC-released Noggin was biologically active in blocking the
BMP signaling in in vitro mesenchyme limb micromasses as well as in ex-vivo limb cultures.
Results reveal that HGC is a valuable protein-delivery system in developmental biology.
Keywords
Embryonic mouse limb implant; Hydrophobically modified glycol chitosan; Protein delivery
system; Developmental biology; Skeletogenesis
© 2009 Elsevier B.V. All rights reserved.
*Author of correspondence: University of North Carolina at Chapel Hill, Department of Pediatrics, Division of Pediatric
Endocrinology, Mason Farm Road, Campus Box: 7039, Chapel Hill, NC, 27599-7039, USA. Phone: (919) 843-6905;
spagnoa@med.unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Control Release. Author manuscript; available in PMC 2012 May 30.
Published in final edited form as:














Diffusible proteins play critical roles in developmental biology. Ex-vivo cultures of
dissected embryonic organs have been widely used and limb bud cultures in particular have
played a critical role in unraveling pivotal steps of the skeletogenesis process.
Skeletogenesis within the developing limbs is a well organized process that arises from the
condensation of cartilage progenitor cells into a cartilaginous template that is subsequently
replaced by bone to form the adult skeletal elements separated by the joints. The synovial
joints form through segmentation of the continuous cartilaginous template with loss of
differentiated chondrocytes at the sites of the developing joints and emergence of a
nonchondrocytic joint-forming cell population that undergoes condensation, flattens, and
develops an interzone that then cavitates to form the joint space within the articular cartilage
[1, 2]. Joint interzone formation is known to begin at embryonic age (E) 13.5, but there is
limited information on the mechanisms that regulate the complex multistep process. In fact,
very few molecules have been reported to be necessary and/or sufficient to initiate the joint
formation process (namely Noggin and growth and differentiation factor-5 [3, 4]). The
mechanisms through which these molecules regulate the temporally and spatially organized
emergence of joint interzone cells within the chondrogenic condensates are unclear.
One of the approaches to elucidate the mechanisms through which diffusible molecules
regulate limb development is the local implantation of carriers containing the molecule by
injection. Although,numerous micro-carrier materials have been used to deliver molecules
into adult tissues, studies in embryonic tissues are limited and have primarily relied on Affi-
Gel Blue beads [5, 6] or fibrous glass matrix [7, 8]. However, the lack of insight into protein
loading efficiency and the dynamics of protein release pose some issues for the
interpretation of the experimental data. Furthermore, the technical difficulties of implanting
a single agarose bead (size in the order of 50-250 μm) into mouse embryonic paws with
sizes ranging from 1.0 mm x 1.2 mm at E13.5 to 1.5 mm x 1.8 mm at E16.5 represent
critical limitations in the use of these materials. Nanoparticles may represent a novel
approach for this area of developmental biology research that may overcome these
limitations.
Kim et al. reported the preparation of hydrophobically modified glycol chitosan (HGC)
nanoparticles consisting of glycol chitosan conjugated with β-cholanic acid [9-15]. HGC
nanoparticles have been reported to encapsulate and sustainably release various chemicals
and peptides [12-20]. Furthermore, the use of glycol chitosan derivatives is safe because
these materials are biocompatible, biodegradable, and weakly immunogenic [21]. These
characteristics, along with their size (~ 200nm) and adaptability for implants, make the HGC
particularly suitable for delivering proteins into dissected embryonic limbs.
Here we describe: 1) HGC-protein loading, size, morphology and kinetics release of Noggin
and bovine serum albumin (BSA); 2) the retained biological activity of Noggin after release
from HGC; 3) the development of reliable micro-techniques for local implant of HGC as a
carrier to study diffusible molecules into dissected murine limbs, including developing joints
at different embryonic stages without perturbing development; 4) the detectability to HGC
nanoparticles after histological sectioning; 5) the sustained release of diffusible proteins
from implanted HGC into dissected embryonic limbs. Our data reveals the potential of HGC
as a novel protein delivery system which can be used for research in developmental biology.
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2. Materials and Methods
2.1. Materials
Glycol chitosan (MW=2.5×105; degree of deacetylation=82.7%) was purchased from
Sigma-Aldrich. It was dissolved in distilled water, filtered with a 22 μm pore size filter to
remove insoluble impurities. N-hydroxysuccinimide, 5β-cholanic acid, and 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride were obtained from Sigma-Aldrich and
used without further purification. Deionized distilled water (Millipore; resistanceN4MΩ)
was used for HGC synthesis and characterization. Recombinant mouse Noggin was
purchased from R&D and resuspended with BSA at a final concentration of 100 ng/μl for
Noggin and 5 μg/μl for BSA to maintain the stability of the protein as recommended by the
manufacturer. BSA was purchased from Sigma-Aldrich. All chemicals were analytical grade
and used without further purification.
2.2. Preparation of HGC
HGC was prepared as previously reported [22]. Briefly, glycol chitosan (2 μmol, MW =
2.5×105) was dissolved in distilled water (60 mL), followed by dilution with methanol (60
mL) (water/methanol co-solvent (1:1 v/v). 5β-cholanic acid (56 μmol, MW = 360.57) was
added and stirred until the solution was optically transparent. To activate carboxylic acid
pertaining to 5β-cholanic acid, equal amounts (1.5 equiv5β-cholanic acid]) of EDAC (84
μmol, MW=191.70) and NHS (84 μmol, MW = 115.09) were added into the polymer
solution, which allowed formation of the amide linkage by the reaction with primary amino
groups in glycol chitosan. The resulting solution was stirred for 24 hours at room
temperature, dialyzed (molecular weight cutoff = 10 kDa, Spectra Por) for 3 days against the
excess amount of water/methanol mixture (1v/4v), and lyophilized.
2.3. Preparation and characterization of HGC-Noggin and HGC-BSA nanoparticles
Proteins were encapsulated into HGC nanoparticles by a solvent evaporation method as
previously reported with some modifications [14]. HGC (5 mg) was resuspended in 10 ml
solution containing distilled water:ethanol=1:1, then mixed with dH2O (0.17 ml) containing
either BSA (0.5 mg) or Noggin and BSA (respectively Noggin 10 μg and BSA 0.5 mg),
additional ethanol (5 ml) was added to final ratio of distilled water:ethanol=1:2, to obtain
HGC-BSA and HGC-Noggin. The solvents were then evaporated for 6-10 min at 60 °C
using a rotary evaporator to prepare a thin polymer/peptide film. After addition of 5 ml of
distilled water, the solution was gently stirred for 10 min and then filtered (0.8 μm pore size
filter). The resulting solution was purified using the Amicon Ultra-4 system (100 kDa cutoff
membrane) (1600 rpm for about 30 min), unfiltered and filtered solutions (containing
unloaded “free” protein) were collected and lyophilized. Fractions were also collected at
each of the preparation steps and a 25 μl aliquot was used to determine either BSA or
Noggin protein concentration using respectively the Bio-Rad DC protein assay reagents
(Bio-Rad Laboratories) for the HGC-BSA preparation or Noggin western immunoblot
(WIB) analysis for Noggin-HGC preparation. The morphology and size distribution of HGC
nanoparticles, loaded or unloaded with proteins, were characterized using dynamic light
scattering (DLS) (Zetasizer 32, Malvern Instruments) and transmission electron microscopy
(TEM) (JEOL 100CX , located at the Microscopy Laboratory Services Core Facility at
UNC). Five milligrams of HGC, HGC-BSA or HGC-Noggin polymer/peptide films were
resuspended in 5ml dH2O that were either gently shaken for 6 h for HGC or gently stirred
for 10 min for HGC-BSA and HGC-Noggin after evaporation. Thereafter, the solutions were
sonicated 20 times (5 seconds on and 2 seconds off for each time) using a probe-type
sonicator (Sonic Dismembrator Model 500, Fisher Scientific) at 90 W and filtered (0.8 μm
pore size filter). DLS system was operated at 633 nm and 25±0.1 °C. The scattered light,
generated by self-aggregates in distilled water was measured at an angle of 90° and was
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colle cted with a BI-9000AT autocorrelator [23]. TEM images were taken at an accelerating
voltage of 100 kV. Polymer solution (5 μl) with a concentration of 1 mg/ml was placed onto
a carbon-coated copper grid, taped with a filter paper to remove surface water, and air-dried
for 5 min. TEM measurements were carried out after the sample was negatively stained by
2% uranyl acetate [24].
2.4. Noggin and BSA releases from HGC nanoparticles
HGC-Noggin or HGC-BSA nanoparticles (2 mg/ml) were dispersed in PBS. The bulk
solution (600 μL) was placed into a cellulose membrane Float-A Lyzer (MW cutoff = 100
kDa). The Float-A Lyzer was placed in 30 ml of PBS and gently shaken at 37 °C in a water
bath. At various time points, the medium was refreshed. Samples were taken at
predetermined times and concentrated with Amicon Ultra-4 system (5 kDa) into 600 μl.
Samples were saved and 25 μl solutions were used for protein concentration determination
either by Bio-Rad DC protein assay for BSA or WIB analysis for Noggin.
2.5. Proteins released from HGC to treat limb bud micromass cultures
Limb bud micromass cultures were prepared as previously reported [25]. Briefly, limbs were
collected aseptically from E13.5 embryos, teased apart into small pieces and incubated with
dispase (1 U/ml in PBS) (GIBCO BRL) for ~45 minutes at 37 °C. Dispase-digestion was
terminated by cell resuspension in culture medium (CM) (60% Ham’s F12, 40% DMEM
containing 10% FBS). Cells were passed through a No. 20 Nitex (Tetko) mesh to remove
cell clumps. Micromass cultures were initiated by carefully placing 10 μl of the cell
suspension (1×105 cells) into the center of a 24-well plate. Cultures were placed in a cell
incubator at 37°C in 5% CO2. After attachment (~1.5 hour), 1 ml of CM was added and
cultures were returned to the incubator. Media changes were performed at least once a day.
To obtain HGC-released Noggin, 0.1 mg of HGC-Noggin (containing 200 ng ofNoggin), or
HGC, or HGC-BSA were resuspended in 1 ml serum free CM and placed in the incubator
for two days. Collected media were filtered using a 100 kDa Microcon (Millipore) and used
to treat micromass cultures for 20 minutes.
2.6. WIB analysis
Fractions from Noggin loading assay and in vitro release assay as well as total protein
micromass cell lysates were subjected to WIB using ECL reaction (Pierce) as previously
reported [26]. Total protein cell lysates were obtained by solubilizing micromass cell
cultures in 2X SDS sample buffer (20 mM dithiothreitol, 6% SDS, 0.25 M Tris, pH 6.8,
10% glycerol, 10 mM NaF and bromophenyl blue). Total protein concentration was
measured using Bio-Rad DC protein assay; equal amounts of protein (20 μg) were used for
WIB analysis as previously reported [26]. Noggin and phospho-Smad-1,5,8 polyclonal
antibodies were from Cell Signaling. Anti-beta-actin polyclonal antibody was from Sigma-
Aldrich. Anti-rabbit and anti-mouse IgG, horseradish peroxidase (HRP)-conjugated
secondary antibodies were from Amersham Bioscience.
2.7. HGC-BSA nanoparticles implantation and ex-vivo limb cultures
Limb autopods (paws) were dissected either from E13.5, E14.5 or E15.5 C57BL/6 mouse
embryos in ice-cold PBS. Dissected limbs were half embedded inside 1.5% agarose/PBS gel
and placed under an Olympus SZX19 stereo-microscope. Two techniques were developed to
perform HGC or HGC-BSA implants into discrete regions of the autopods. In the first
technique, HGC or HGC-BSA suspensions were implanted using a graduated syringe
mounted with a 33G needle delivering ~1 μl to each limb. In the second technique, a
microinjection unit (Picosprizer II) delivering 0.0015 μl per injection was assembled. The
micro-injection unit was mounted with glass micro-pipettes (Sutter Instrument) that were
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pulled using a P-30 puller (Sutter Instrument) (setting 700 for Heat#1 and 200 for pull
force). The tip of the pipette was cut to obtain a diameter of 50 μm. Injection was performed
using high pressured nitrogen set at 36.5 PSI for 3 milliseconds. Using the micro-injector,
small site implants (joint site) were performed by delivering 1-3 shots. For large site
implants (metatars or metacarps, or whole paw), about 40 shots were delivered. Implanted
limbs were cultured in BGJb medium (Gibco BRL) supplemented with penicillin/
streptomycin (Gibco BRL). The limbs were incubated in a tissue culture incubator. Images
were taken right after injection or 2-3 days after injection/culture under a SZX19
stereomicroscope equipped with a DP71 digital camera (Olympus) and were imported into
Photoshop (Adobe), where they were formatted without using any imaging enhancement.
For timed pregnancies, noon of the day when evidence of a vaginal plug was found was
considered E0.5. Protocols were approved by the University of North Carolina at Chapel
Hill Institutional Animal Care and Use Committee.
2.8. Cibacron Brilliant Red-3BA and Hematoxylin staining
Cibacron Brilliant Red-3BA (Aldrich Chem.) 0.03% staining was performed according to
the previously published protocol [27] with some modifications. Briefly, paraffin sections (6
μm) and frozen sections (20 μm) were obtained using standard procedures, as previously
reported [2].Sections were hydrated with ddH2O and then stained with Hematoxylin for 3
minutes. After washing in running tap water for 5 minutes in a 2L beaker and rinsed in 2
changes of ddH2O (2 minutes per change), sections were stained in CBR-3BA stain solution
(pH 3.2) for 3 minutes. After rinsing in 2 changes of ddH2O (2 minutes per change.),
sections were dehydrated in 2 changes each of: 95% alcohol (2 minutes per change) and
absolute alcohol (2 minutes per change). Finally, sections were washed in 3 changes (2
minutes per change) of CitriSolv and mounted with resinous medium.
2.9. BSA, pSmad1,5,8 and Noggin immunohistochemistry (IHC)
Anti-BSA-HRP antibody was from ABcam. Frozen sections were blocked with 2% normal
goat serum in PBS-Tween for 1 hour at room temperature and incubated with anti-BSA-
HRP antibody at 4°C overnight. Sections were then incubated in avidin-biotin peroxidase
complex solution from Vector Laboratories for 30 minutes at room temperature and
peroxidase activity was visualized with a 3,3′ diaminobenzidine substrate kit (Vector). Anti-
pSmad1,5,8 antibody and anti-Noggin antibody were from Cell Signaling. Paraffin sections
were used to perform pSmad1,5,8 and Noggin IHC according tomanufacturers’ protocol.
3. Results
3.1. BSA and Noggin can be loaded into HGC nanoparticles with high efficiency, size and
morphology after loading
It has been reported that nano-sized HGC can encapsulate and release small peptides (MW
~600 Da) [17]. To determine whether HGC nanoparticles can encapsulate larger proteins,
we used BSA (MW = 66,000 Da) and Noggin (MW = 33,000 Da). Self-assembled HGC-
Noggin embedded nanoparticles were prepared according to the strategy schematically
presented in Figure 1A. To verify protein loading efficiency to HGC nanoparticles, fractions
were collected (fractions designated as F1 to F4) at each of the preparation and purification
steps. HGC-BSA nanoparticles were prepared similarly and fractions were subjected to
quantitative colorimetric BSA assay. The loading efficiency of BSA to HGC, expressed as
the percentage of the starting concentration (F1) to the concentration detected in the final
fraction (F4), was determined to be 84±3% (n=3 distinct preparations). Fractions obtained
during HGC-Noggin preparation were subjected to WIB. The single anti-Noggin reactive
band detected was quantified by densitometric analysis (Figure 1B). Serial dilutions of
native Noggin protein starting solution were used to generate an internal standard curve to
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semi-quantify concentration of Noggin in the fractions (Figure 1B). The loading efficiency
of Noggin to HGC (percentage of F4/F1) was 93±4% (n=3 distinct preparations). Noggin
protein was undetectable in the F3 fraction containing unloaded (free) protein, confirming
the high loading efficiency of HGC for Noggin (Figure 1B). Results show that HGC
nanoparticles are capable of high loading efficiency of the relatively high molecular weight
proteins BSA and Noggin.
To determine the size and morphology of HGC after protein loading we performed DLS and
TEM analyses. As shown in Figure 2, the mean diameter of HGC nanoparticles is 211±14
nm (n=3) (Figure 2A), HGC-BSA and HGC-Noggin (containing BSA) had larger mean
diameters of 360±16 nm (n=3) (Figure 2B) and 357±6 nm (n=3), respectively (Figure 2C).
The similar diameters of HGC-BSA and HGC-Noggin nanoparticles is explained by the fact
that both preparations were loaded with BSA with a ratio of Noggin:BSA of 1:50 for HGC-
Noggin. TEM analyses indicate that HGC-BSA or HGC-Noggin loaded nanoparticles
display a spherical morphology similar to unloaded HGC but larger in size. To determine
HGC-protein stability, DLS analyses were performed daily for 5 days on HGC, HGC-BSA
and HGC-Noggin preparations at a physiological pH (in PBS, pH7.4) and maintained at 4
°C. As shown in Figure S1, no significant changes in the average size were observed in the
protein loaded and unloaded preparations.
3.2. HGC nanoparticles demonstrate excellent properties for the sustained release of
proteins in vitro
To characterize the release of Noggin and BSA from HGC-Noggin and HGC-BSA
respectively, we performed a time-course release profile by dialysis (100 kDa Floater-A-
Lyzer). The protein release profile from HGC nanoparticles was determined in PBS (pH 7.4)
at 37°C, maintaining the protein gradient by regularly replacing the PBS dialysate solution
at various time points (Figure 3A). Each solution was mixed with the previous and subjected
to Noggin WIB analysis (Figure 3B). Noggin protein was quantified by densitometric
analyses. Serial dilutions of recombinant Noggin solution were used to generate an internal
standard curve to evaluate the concentration of Noggin (Figure 3C). The Noggin release
profile showed that 87±5% (n=3 distinct experiments) of the protein was released, from the
HGC nanoparticles within 48 hours following linear kinetics; a minimal additional release
was observed after that time (94±7% after 72 hours) (Figure 3C). BSA had a similar HGC
release profile with 84±3% released after 48 hours. These results show that HGC
nanoparticles comprise excellent properties for a sustained release of protein at a
physiological pH.
3.3. Noggin retains biological activity after loading and release from HGC
Noggin binding to BMPs depends on its ability to forms dimers [28]. Performing Noggin
WIB under non-reducing conditions we showed that Noggin loaded into HGC remained
capable of forming dimers (Figure 4A). Furthermore, in order to determine whether HGC-
released Noggin maintained its biological activity we performed a Smad-1,5,8
phosphorylation assay in limb bud mesenchyme micromasses. To obtain HGC-released
Noggin, HGC-Noggin and control HGC were incubated in serum free media for 48 hours.
Control media or Noggin-containing media (200 ng/ml) were collected, and used to treat
limb bud micromasses for 20 minutes, after which cell lysates were collected and subjected
to WIB for phosphorylated Smad-1,5,8. As a positive control, cells were treated under the
same conditions with native Noggin (200 ng/ml). As shown in Figure 4B, we found that
HGC-released Noggin inhibited Smad-1,5,8 phosphorylation similarly to native Noggin.
These results suggest that the biological activities of Noggin are not impaired by
encapsulation in the HGC carrier.
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3.4. HGC-BSA nanoparticles can be implanted throughout the autopod mesenchyme
without interfering with mice limb joint development
To address if HGC nanoparticles can be used as a novel protein delivery system for ex-vivo
research in developmental biology, we tested the properties of HGC-loaded protein injected
into dissected limb buds. We first implanted HGC-BSA and HGC mixed with Methylene
Blue (to mark the injected sites) into dissected E13.5 autopods (paws) or E14.5 autopods
(Figure S2A) using a syringe mounted with a 33G needle. Injections were performed either
in the carpal or the tarsal regions (Figure S2A). As shown in Figure S2B, after culturing the
autopods for 2-3 days, Methylene Blue/HGC was detectable within the whole limb
mesenchyme region (phalanges, carpal/tarsal and metacarpal/metatarsal regions) indicating
that this injection technique can be used to deliver HGC-protein throughout the entire
autopod. To determine whether the implanted HGC nanoparticles interfered with the limb
skeletal development, we performed hematoxylin staining of E13.5 cultured limbs. As
depicted in Figure S2B, we found that HGC as well as HGC-BSA did not interfere with the
skeletal development of the digits, including joint development. However, in E13.5 we
noted some damage at the site where the needle was inserted (Figure S2A, asterisk).
3.5. HGC-BSA nanoparticles can be implanted in discrete regions and at different
embryonic stages of developing autopods using a micro-injection system
In order to achieve implantation of HGC-protein within discrete developing autopod regions
(i.e. at the developing joint site) and to deliver a controlled volume (nanoliter per injection),
we have assembled a micro-injection unit equipped with a micropipette puller (to prepare
calibrated pipettes) and a PicoSpritzer fluid dispensing system, as described in the Methods
section. To fit our implantation site needs, we pulled glass pipettes to a tip diameter of 50
μm after tip cutting, to approximately one seventh of the diameter of a 33G needle (Figure
S3). Mounting the pulled pipettes into the fluid-dispensing system, we implanted HGC-BSA
nanoparticles at either the proximal interphalangeal joint or the distal interphalangeal joints
of E13.5 and E15.5 embryos (Figure 5). E13.5 is the embryonic stage when the joint starts to
develop, forming an interzone within the phalange ossification centers; at E15.5 the joint
space is fully developed. The proximal interphalangeal joint was identified as the site
between the distal part of the metatarsal/metacarpal region and the ending of the interdigital
space; the distal joint was identified as a distal bending within the developing phalange.
Using the micro-injection system, we were able to implant HGC-BSA (Figure 5). The
loaded pipette was gently inserted (insertion site marked as a red circle in Figure 5) into the
digits along the distal or proximal direction with an angle of about 20-30° for ~ 0.1-0.2 mm
and 1 to 3 shots (0.0015-0.0045μl) were injected (delivery site marked blue by Methylene
Blue and indicated by black arrows in Figure 5). No fluid diffusion was noted in the digits
adjacent to the injection site even after culturing. Using the micro-injection system, we were
also able to inject a wide range of volumes (from 0.005 μl up to 0.1 μl) of HGC-BSA into
discrete regions of the developing limbs. Furthermore, HGC or HGC-BSA implantations did
not cause any apparent tissue damage and did not interfere with the limb skeletal
development (Figure 8) at any developmental stage tested. Our data demonstrate the
versatility of our delivery system that allows varying volumes of HGC nanoparticles
carrying proteins to be precisely implanted into discrete regions of developing limbs, at
different embryonic limb development stages.
3.6. Detection of HGC nanoparticles and BSA after implant of HGC-BSA in developing
autopods by histological analysis
To determine whether HGC and HGC-BSA nanoparticles implanted into developing limbs
can be detected in histological sections we used CBR-3BA staining. E15.5 limbs were
implanted with HGC, HGC-BSA or left non-injected and adjacent frozen sections were
either subjected to CBR-3BA staining or BSA-immunohistochemistry (IHC) (Figure S4).
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We found that HGC and HGC-BSA nanoparticles implanted into developing autopods
stained uniquely red with CBR-3BA, while no staining was detectable in limbs that were left
non-injected (Figure 6A-C). To determine whether BSA was detectable within the
developing limbs implanted with HGC-BSA we performed IHC for BSA. We reasoned that
since BSA is not produced in rodents, BSA-IHC would detect only the BSA that is delivered
by HGC. As shown in Figure 6D, we found that BSA was detected within the developing
limb mesenchyme cells implanted with HGC-BSA (4 hours after implant), while no signal
was detectable in limbs implanted only with HGC (Figure 6E) or left non-injected (Figure
6F). Smaller magnifications (20X) of the CBR-3BA staining and BSA-IHC are depicted in
Figure S4. Data demonstrate that a relatively small volume of injected HGC can be detected
using CBR-3BA staining. We also performed BSA-IHC analysis in E15.5 autopods that
were cultured for 1 and 2 days after HGC-BSA implantation. As a control, autopods were
injected with native BSA (lacking the HGC carrier) delivering the same injection volume
and concentration. As shown in Figure 7 A-C, BSA released from HGC was detectable right
after implantation (7A), and 1 day (7B) and 2 days (7C) after implant/culture. In autopods
injected with native BSA (Figure 7 D-F), while BSA immunostaining was evident right after
injection (7D) it was undetectable 1 day (7E) and 2 days (7F) after organ injection/culture.
Our findings indicate that HGC is a suitable carrier for the sustained release of proteins in
cultured autopods.
3.7. Implanted HGC-Noggin is detectable and inhibits phosphorylation of Smad1,5,8 in ex-
vivo cultured embryonic limbs
To determine whether Noggin was released after implant into embryonic limbs and retained
its biological activity, IHC for Noggin and Smad-1,5,8 was performed in adjacent paraffin
sections obtained from E14.5 autopods injected either with HGC-Noggin (Figure 8B’ and
8B”) or HGC-BSA (Figure 8A’ and 8A”) and cultured for 12 hours after implantation. As
shown in Figure 8, a strong positive immunostaining for Noggin was detected (Figure 8B’,
red arrows) in the HGC-Noggin-injected region of the limbs, while minimal staining
(indicating the endogenous Noggin) was detected in the corresponding region injected with
HGC-BSA (Figure 8A’). Phosphorylation of Smad1,5,8 was inhibited in the same region in
which injected Noggin was detected (Figure 8B”, black arrows), but not in the
corresponding region injected with HGC-BSA (Figure 8A”). These findings indicate that
Noggin was released in implanted/cultured limbs and was biologically active.
4. Discussion
In our studies we have: 1) shown that HGC nanoparticles allow high loading efficiency and
sustained biologically unaltered release of the relatively high molecular weight proteins
BSA and Noggin; 2) developed several techniques to inject HGC-proteins into dissected
mouse embryonic limbs including assembling a micro-injector system; 3) demonstrated the
versatility of our delivery techniques to dispense HGC-protein at different gestational ages
and within discrete regions; 4) identified HGC nanoparticles in histological preparations of
HGC-protein injected embryonic limb organs; 5) detected the release of BSA and Noggin
from HGC in injected limb organs; 6) demonstrated that Noggin released from HGC
retained its biological activity of blocking the BMP signaling in in vitro mesenchyme limb
micromasses as well as in ex-vivo limb cultures.
Embryonic organ cultures have been crucial in unrevealing critical aspects of the
development process. Ex-vivo embryonic organ cultures are superior to in vivo
transplantation or isolated cell cultures in many aspects. The cultured tissues can be
manipulated in multiple ways, and their development can be continuously monitored. The
culture conditions are reproducible, and the composition of the medium is known exactly
and can be modified. Furthermore, the ex-vivo culture conditions allow analyses of the
Li et al. Page 8













embryonic tissue interactions (i.e. epithelial-mesenchymal) and of the nature of the inductive
signals. The potentials for embryonic organ cultures to study the local long-term effects of
diffusible molecules in morphogenesis have been hampered by the use of limiting and
uncharacterized protein carriers. The Affi-gel agarose beads have been widely applied [5,
29-32]. Beads are 50-250 μm in diameter, are routinely used for protein purification and are
composed of crosslinked agarose mesh with covalently attached Cibachrome blue F3GA
dye. Although these carriers have the ability to absorb peptides in solution, the kinetics of
protein release after in vivo or ex-vivo implantation is basically unknown. Furthermore,
considering the relatively large size of the beads, single bead implantation into mouse
embryonic tissues at early developmental stage is problematic, and since the bead’s size is
highly variable, protein binding per bead is unpredictable. Similar issues can be raised for
the studies that employed fibrous glass matrix containing proteins, although these carries can
be more easily implanted [7, 8]. Here, we characterized the loading and release properties of
HGC for BSA and Noggin and developed suitable techniques for local implantation into
embryonic limbs. We used the embryonic limbs as a model because it allows to study the
development of specific skeletal tissues, for example joints that are highly organized and
develop through temporally and spatially well-defined morphogenic stages that are
reproducible in the ex-vivo organ cultures.
Several studies have shown that HGC nanoparticles through enhanced permeability have
efficient delivery properties for tissue targeting in vivo and in vitro [10, 11, 13-15, 17-19,
22, 33]. Furthermore, the subcellular size of HGC, biocompatibility and biodegradability are
additional valuable characteristics at a pharmacologically relevant level. Herein, we report a
novel application of HGC in embryonic organ cultures and show that implantation of HGC-
proteins in a focal manner results in production of targeted, detectable and imageable levels
of sustained released proteins that retain their biological activities.
Delivery of carriers into embryonic tissues for achieving prolonged availability and
maintaining efficient local concentration needs to be performed using relatively small
volumes (in the order of μ/nano-liters), in relatively small regions (in the order of μm). We
have assembled a micro-injection unit with those specific characteristics and set the delivery
pressure and pipette caliber parameters that allow an efficient and reproducible implantation
of HGC-nanoparticles into dissected embryonic limbs without interfering with development
and without causing any damage. The bench unit can be easily assembled with
commercially available equipment and requires limited space. In addition we have
determined the appropriate suspension volume for HGC-protein that leads to an adequate
viscosity for the injection with minimal diffusion at the site.
In summary, we have showen that HGC can be used as a valuable protein delivery system in
developmental biology research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HGC-Noggin preparation. (A) Schematic representation of the strategy used to obtain
purified HGC-Noggin preparation. (B) Noggin WIB of fractions obtained during the
loading-purification process. Starting solution (F1), after loading-evaporation (F2), unloaded
“free” fraction (F3) and loaded fraction (F4). To evaluate the concentration of Noggin in the
fractions, an internal standard curve using serial dilutions of recombinant Noggin was used.
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Size distribution and morphology of (A) HGC nanoparticles, (B) HGC-BSA nanoparticles
and (C) HGC-Noggin(BSA) nanoparticles, determined by DLS and TEM analyses.
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Time-course analysis of Noggin release from HGC. (A) Refreshing dialyzing solution was
obtained at the indicated time points. (B) Time-course of HGC-Noggin release by Noggin
WIB analysis. a, HGC-Noggin, before release (expected 20ng); b, Released Noggin after 16
hours, S1; c, Released Noggin after 24 hours, S1+S2; d, Released Noggin after 40 hours,
S1+S2+S3; e, Released Noggin after 48 hours, S1+S2+S3+S4; f, Released Noggin after 64
hours, S1+S2+S3+S4+S5; g, Released Noggin after 72 hours, S1+S2+S3+S4+S5+S6; h,
Remaining Noggin; i-m, Noggin Standard curve: 1ng, 2ng, 5ng, 10ng, 20ng. (C) Release
profile of Noggin from HGC-Noggin nanoparticles; three distinct data sets were obtained
from respective WIB analyses that were averaged and represented as mean±standard
deviation.
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Noggin loaded and released from HGC maintains its biological activity. (A) HGC-Noggin
maintains the ability to form dimers as determined by Noggin WIB under non-reducing
conditions. (S0): native Noggin; (S4): Noggin loaded to HGC. (B) Noggin released from
HGC inhibits Smad-1,5,8 phosphorylation. HGC-Noggin, HGC-BSA, HGC alone were
incubated for 48 hours in SF medium that was collected, dialyzed and used to treat limb
mesenchyme micromasses for 20 minutes. a, control medium; b, medium from HGC alone;
c, medium from HGC-BSA; d, medium from HGC-Noggin; e, 200 ng of native Noggin
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HGC-BSA nanoparticles can be implanted into developing autopods using a microinjection
unit. Dissected autopods from wild type C57BL/6 mice at either E13.5 (A-C) or E15.5 (D-L)
were imaged before injection (non-injected, left panels) and then subjected to Methylene
Blue-HGC-BSA implantation at one site (middle panels) followed by a second site (right
panels). Red circles indicate the position where the pipette was inserted. Black arrows
indicate where the Methylene Blue-HGC-BSA implants were delivered. Picture was taken
immediately after delivery. See text for more details.
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Implanted HGC-BSA can be visualized with CBR-3BA staining and IHC for BSA.
CBR-3BA staining (A-C) was performed on frozen sections from wild type C57BL/6 mice
at E15.5 implanted either with HGC-BSA (A) or HGC (B) or left non-injected (C). IHC for
BSA was performed on adjacent frozen sections (D-F). 100X magnifications are depicted.
Pictures of unsectioned limbs as well as 20X magnifications including the region from
where the 100X magnifications were obtained can be found in Figure S4
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Implanted HGC-BSA showed sustained BSA release. BSA IHC was performed on frozen
sections from wild type C57BL/6 mice at E15.5 implanted either with HGC-BSA (A-C), or
native BSA (D-F) and cultured for 1 and 2 days. 100X magnifications are depicted.
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HGC-Noggin is released and inhibits Smad-1,5,8 phophorylation after implantation into
embryonic limbs and ex-vivo culturing. Noggin IHC and pSmad1,5,8 IHC were performed
on adjacent paraffin sections obtained from E14.5 autopods implanted either with HGC-
BSA (A) or HGC-Noggin (B). 20X and 100X magnifications are depicted. Red arrows
indicate Noggin IHC and black arrows indicate inhibited Smad-1,5,8 phosphorylation in the
same region.
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